CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 19:04:21 19/06/2024 BST | ||
| 13.86 EUR | -2.67% |
|
| Current month | +13.74% | ||
| 1 month | +19.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 13.86 | -2.67% |
| 18/06/24 | 14.24 | -4.56% |
| 17/06/24 | 14.92 | -3.05% |
| 14/06/24 | 15.39 | +1.72% |
| 13/06/24 | 15.13 | +2.79% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 07:04 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GGA |
| ISIN | DE000VU8GGA5 |
| Date issued | 13/06/2023 |
| Strike | 319.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.67 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.66 € |
|---|---|
| Lowest since issue | 3.81 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Certificates
- Certificat